Triple-negative breast cancer in the older population

Annals of Oncology

Volumn 23, Issue SUPPL. 6, 2012, Pages

  Aapro, M ^a   Wildiers, H ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Elderly; Geriatric; Prognosis; Treatment; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; HORMONE RECEPTOR; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN;

AGED; ARTERY THROMBOSIS; ARTICLE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; METRONOMIC DRUG ADMINISTRATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; TRIPLE NEGATIVE BREAST CANCER; VEIN THROMBOSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 84867131803     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds189     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer 2010; http://globocan.iarc.fr (6 January 2012, date last accessed).
2. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-1728.
3. Biganzoli L, Wildiers H, Oakman C et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13: e148-e160.
4. Wildiers H, Kunkler I, Biganzoli L et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007; 8: 1101-1115.
5. Yu KD, Li JJ, Di GH et al. A straightforward but not piecewise relationship between age and lymph node status in Chinese breast cancer patients. PLoS One 2010; 5: e11035.
6. Dreyer G, Vandorpe T, Smeets A et al. Triple-negative Breast Cancer: Clinical Characteristics in the Different Histological Subtypes. Proceedings of the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX; AACR Philadelphia, PA: Abstr P3-10-05.
7. Cheung K, Syed BM, Green AR et al. Clinical outcome of triple-negative primary breast cancer in older women: comparison with their younger counterparts. J Clin Oncol 2011; 29(Suppl): Abstr 1057.
8. Thike AA, Iqbal J, Cheok PY et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 2010; 34: 956-964.
9. Billar JA, Dueck AC, Stucky CC et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol 2010; 17(Suppl 3): 384-390.
10. Malone KE, Daling JR, Doody DR et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006; 66: 8297-8308.
11. Bouchardy C, Rapiti E, Fioretta G et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003; 21: 3580-3587.
12. Wildiers H. Challenges in treating older cancer patients: breast cancer. Ann Oncol 2008; 19(Suppl 7): vii99-103.
13. Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293: 1073-1081.
14. Clarke M, Coates AS, Darby SC et al. Adjuvant chemotherapy in oestrogenreceptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008; 371: 29-40.
15. Elkin EB, Hurria A, Mitra N et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 2006; 24: 2757-2764.
16. Giordano SH, Duan Z, Kuo YF et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24: 2750-2756.
17. Muss HB, Berry DA, Cirrincione CT et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360: 2055-2065.
18. Fargeot P, Bonneterre J, Roche H et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004; 22: 4622-4630.
19. Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25: 3808-3815.
20. Jones S, Holmes FA, O'Shaughnessy J et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27: 1177-1183.
21. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32.
22. Aapro M, Schwenkglenks M, Lyman GH et al. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 2010; 74: 203-210.
23. Janssen-Heijnen ML, Extermann M, Boler IE. Can first cycle CBCs predict older patients at very low risk of neutropenia during further chemotherapy? Crit Rev Oncol Hematol 2011; 79: 43-50.
24. Aapro M, Monfardini S, Jirillo A et al. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev 2009; 35: 503-508.
25. Feher O, Vodvarka P, Jassem J et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005; 16: 899-908.
26. Aapro M, Bernard-Marty C, Brain EG et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 2011; 22: 257-267.
27. Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004; 30: 333-342.
28. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155-2161.
29. Blum JL, Kohles J, McKenna E et al. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat 2011; 125: 431-439.
30. Mikhail SE, Sun JF, Marshall JL. Safety of capecitabine: a review. Expert Opin Drug Saf 2010; 9: 831-841.
31. Colleoni M, Rocca A, Sandri MT et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73-80.
32. Colleoni M, Orlando L, Sanna G et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006; 17: 232-238.
33. Salem DA, Gado NM, Abdelaziz NN et al. Phase II trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer. J Egypt Natl Canc Inst 2008; 20: 134-140.
34. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
35. O'Shaughnessy J, Dieras V, Glaspy J et al. Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). Cancer Res 2009; 69(24 Suppl): Abstr 207.
36. Biganzoli L, Di Vincenzo E, Jiang Z et al. First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study. Ann Oncol 2012; 23: 111-118.
37. Smith IE, Pierga JY, Biganzoli L et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol 2011; 22: 595-602.
38. Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol 2011; 29: 1232-1235.